Developing the High-Performance Medical Affairs Function: Study Excerpt
In today's challenging healthcare environment, medical affairs' role has become even more crucial to pharmaceutical companies' success. Confronted with declining R&D productivity, escalating development costs, increasing competition, growing price pressures, and intensified regulatory and public scrutiny, pharmaceutical companies seek to maintain double-digit revenue and earnings growth demanded by investors. This white paper highlights findings from a larger research effort undertaken by Best Practices, LLC to benchmark the organization and structure of medical affairs departments at top pharmaceutical companies.
Industries Profiled:
Pharmaceutical; Biotech; Health Care
Companies Profiled:
Abbott Laboratories; Roche; Amgen; AstraZeneca; Eli Lilly; Merck
|